$VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Jayson Rieger
CEO
71
Employees
$5.69
Current Price
$59.79M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 2 | 2 | $34,637.60 | 7,030 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 4 | 6 | $210,889.60 | 42,230 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 4 | 6 | $210,889.60 | 42,230 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 4 | 6 | $210,889.60 | 42,230 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Zawitz David Chief Operating Officer | Purchase | 6,000 | $4.98 | $29,880.00 | View Details |
| Aug 17, 2026 | Rosenberg Noah L. CMO | Purchase | 4,200 | $4.91 | $20,622.00 | View Details |
| Aug 14, 2026 | Rieger Jayson Director | Purchase | 20,000 | $5.06 | $101,200.00 | View Details |
| Aug 18, 2026 | Rosenberg Noah L. CMO | Purchase | 2,030 | $4.92 | $9,987.60 | View Details |
| Aug 17, 2026 | Rieger Jayson Director | Purchase | 5,000 | $4.91 | $24,550.00 | View Details |
| Aug 18, 2026 | Kirby John J. Interim CFO | Purchase | 5,000 | $4.93 | $24,650.00 | View Details |
6 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.58
ActualN/A
Revenue
Estimated$6.41M
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.41
ActualN/A
Revenue
Estimated$5.73M
ActualN/A
EPS
Estimated-$0.39
Actual-$0.62
Miss
Revenue
Estimated$5.73M
Actual$5.86M
Beat
5 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: